September 6th 2024
Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
First-in-Class Targeted Agent Shows Activity in Refractory Multiple Myeloma
December 10th 2013According to data presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, a first-in-class targeted agent demonstrated activity in patients with relapsed and refractory multiple myeloma.
Read More
New Standard of Care Established in Newly Diagnosed Multiple Myeloma
December 9th 2013In patients with transplant-ineligible NDMM, the combination of continuous lenalidomide and low-dose dexamethasone (continuous Rd) extends PFS and trends toward improving OS compared with the standard combination of MPT.
Read More
Early Intervention in Smoldering Myeloma May Delay Progression
December 9th 2013CRs were seen in a group of high-risk patients following intervention in early or “smoldering†myeloma with a three-drug regimen, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.
Read More
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myeloma
October 19th 2013In an updated analysis of the phase III MM-003 trial, Celgene International Sarl, the makers of pomalidomide, reported on a new progression-free survival (PFS) analysis and final overall survival (OS) in September 2013.
Read More
Transforming Expectations and Outcomes With Targeted Therapies
October 18th 2013With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer
Read More
Pomalidomide Labeled an Advance in Multiple Myeloma
December 9th 2012The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Read More